CY1761A - Aerosol composition comprising nitroglycerin as active ingredient - Google Patents
Aerosol composition comprising nitroglycerin as active ingredient Download PDFInfo
- Publication number
- CY1761A CY1761A CY176194A CY176194A CY1761A CY 1761 A CY1761 A CY 1761A CY 176194 A CY176194 A CY 176194A CY 176194 A CY176194 A CY 176194A CY 1761 A CY1761 A CY 1761A
- Authority
- CY
- Cyprus
- Prior art keywords
- component
- weight
- nitroglycerin
- composition
- glycol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 63
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 title claims description 54
- 229960003711 glyceryl trinitrate Drugs 0.000 title claims description 53
- 239000000006 Nitroglycerin Substances 0.000 title claims description 52
- 239000000443 aerosol Substances 0.000 title claims description 10
- 239000004480 active ingredient Substances 0.000 title claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 35
- 235000019441 ethanol Nutrition 0.000 claims description 28
- 239000003380 propellant Substances 0.000 claims description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 238000011049 filling Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 26
- 239000007789 gas Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 239000007921 spray Substances 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 8
- 235000013772 propylene glycol Nutrition 0.000 description 8
- 229960004063 propylene glycol Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 230000036765 blood level Effects 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000000654 additive Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003975 dentin desensitizing agent Substances 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/30—Materials not provided for elsewhere for aerosols
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU883585A HU199678B (en) | 1988-07-08 | 1988-07-08 | Process for producing aerosols containing nitroglicerol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1761A true CY1761A (en) | 1994-07-15 |
Family
ID=10964655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY176194A CY1761A (en) | 1988-07-08 | 1994-07-15 | Aerosol composition comprising nitroglycerin as active ingredient |
Country Status (15)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104984351A (zh) * | 2015-06-15 | 2015-10-21 | 马应龙药业集团股份有限公司 | 一种硝酸甘油丙二醇溶液的制备方法 |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4007705C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1990-03-10 | 1991-09-26 | G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De | |
| US5370862A (en) * | 1990-06-13 | 1994-12-06 | Schwarz Pharma Ag | Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina |
| DE4018919C2 (de) * | 1990-06-13 | 1994-08-25 | Sanol Arznei Schwarz Gmbh | Nitroglycerin-Spray |
| DE4026072A1 (de) * | 1990-08-17 | 1992-02-20 | Sanol Arznei Schwarz Gmbh | Nitroglycerinhaltiger, hydrophiler, waessriger pumpspray |
| DE4038203A1 (de) * | 1990-11-30 | 1992-06-04 | Kali Chemie Pharma Gmbh | Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen |
| WO1995032715A1 (en) * | 1994-05-27 | 1995-12-07 | Neptune Pharmaceutical Corporation | Nitric oxide donor composition and method for treatment of anal disorders |
| TW537903B (en) * | 1995-06-27 | 2003-06-21 | Boehringer Ingelheim Kg | New stable pharmaceutical preparation for producing propellant gas-free aerosols |
| WO1997038662A2 (en) * | 1996-04-12 | 1997-10-23 | Flemington Pharmaceutical Corporation | Buccal polar spray or capsule |
| US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
| US20030077228A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
| US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
| US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
| US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
| US20040136914A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
| EP2042161A1 (en) * | 1997-10-01 | 2009-04-01 | Novadel Pharma Inc. | Propellant-free spray composition comprising anti-emetic agent |
| US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
| US20050281752A1 (en) * | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
| US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
| US20090162300A1 (en) * | 1997-10-01 | 2009-06-25 | Dugger Iii Harry A | Buccal, polar and non-polar spray containing alprazolam |
| US20050287075A1 (en) * | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| DE19855097A1 (de) * | 1998-11-28 | 2000-05-31 | Wella Ag | Pigmenthaltiges, verschäumbares Gel |
| WO2000047203A1 (en) * | 1999-02-12 | 2000-08-17 | Mqs, Inc. | Formulation and system for intra-oral delivery of pharmaceutical agents |
| US10004684B2 (en) | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
| GB0417675D0 (en) * | 2004-08-09 | 2004-09-08 | Futura Medical Dev Ltd | Composition for promoting vascular smooth muscle relaxation |
| WO2006089082A2 (en) * | 2005-02-17 | 2006-08-24 | Velcera Pharmaceuticals | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
| GB0602224D0 (en) * | 2006-02-03 | 2006-03-15 | Futura Medical Dev Ltd | Composition for promoting vascular smooth muscle relaxation |
| JP2009534387A (ja) * | 2006-04-19 | 2009-09-24 | ノヴァデル ファーマ インコーポレイテッド | 安定な含水アルコール性経口噴霧調剤物および方法 |
| JP2010513525A (ja) * | 2006-12-22 | 2010-04-30 | ノヴァデル ファーマ インコーポレイテッド | 安定な抗嘔吐経口噴霧製剤および方法 |
| MX2009012109A (es) * | 2007-05-10 | 2010-02-22 | Novadel Pharma Inc | Composiciones contra el insomnio y metodos. |
| DE202008008079U1 (de) * | 2008-06-16 | 2008-09-04 | G. Pohl-Boskamp Gmbh & Co. Kg | Pharmazeutische Zubereitung in Wasserdampf durchlässigen Behältern mit verbesserter Stabilität |
| EP2467128B1 (en) | 2010-08-03 | 2016-04-13 | G. Pohl-Boskamp GmbH & Co. KG | Use of glyceryl trinitrate for treating traumatic edema |
| WO2012113563A1 (en) | 2011-02-25 | 2012-08-30 | G. Pohl-Boskamp Gmbh & Co. Kg | Packaging of solid pharmaceutical preparations containing the active substance glyceryl trinitrate |
| US9248099B2 (en) | 2012-05-31 | 2016-02-02 | Desmoid Aktiengesellschaft | Use of stabilized granules containing glyceryl trinitrate for arteriogenesis |
| ES2617494T3 (es) | 2012-05-31 | 2017-06-19 | G. Pohl-Boskamp Gmbh & Co. Kg | Inducción de arteriogénesis con un donador de óxido nítrico tal como nitroglicerina |
| EP2878310B1 (en) * | 2013-11-29 | 2017-01-11 | G. Pohl-Boskamp GmbH & Co. KG | Sprayable aqueous composition comprising glyceryl trinitrate |
| CN113125596B (zh) * | 2021-04-07 | 2023-01-13 | 马应龙药业集团股份有限公司 | 一种高效液相色谱法测定硝酸甘油软膏中有关物质的方法 |
| WO2025115019A1 (en) | 2023-11-30 | 2025-06-05 | Padagis Israel Pharmaceuticals Ltd. | Stable nitroglycerin formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE632504A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1962-05-24 | |||
| US4001391A (en) * | 1969-04-18 | 1977-01-04 | Plough, Inc. | Means for depositing aerosol sprays in buttery form |
| US4369173A (en) * | 1974-11-27 | 1983-01-18 | Wickhen Products, Inc. | Antiperspirant compositions |
| IL61721A (en) * | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
| DE3109783C2 (de) * | 1981-03-13 | 1987-04-02 | Schwarz GmbH, 4019 Monheim | Verfahren zur Herstellung einer ethanolfreien Nitroglycerinlösung mit einer Konzentration von etwa 1 mg Nitroglycerin/ml |
| US4440777A (en) * | 1981-07-07 | 1984-04-03 | Merck & Co., Inc. | Use of eucalyptol for enhancing skin permeation of bio-affecting agents |
| DE3246081A1 (de) * | 1982-12-13 | 1984-06-14 | G. Pohl-Boskamp GmbH & Co Chemisch-pharmazeutische Fabrik, 2214 Hohenlockstedt | Nitroglycerin-spray |
| EP0175671A1 (de) * | 1984-08-23 | 1986-03-26 | Kuhlemann & Co. | Pharmazeutische Zubereitung sowie Verfahren zum Darreichen dieser pharmazeutischen Zubereitung |
| US4885173A (en) * | 1985-05-01 | 1989-12-05 | University Of Utah | Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities |
| DE3613187A1 (de) * | 1986-04-18 | 1987-10-22 | Mack Chem Pharm | Verwendung einer carbonsaeure in zur topischen anwendung bestimmten pharmazeutischen zubereitungen |
| JPH0645538B2 (ja) * | 1987-09-30 | 1994-06-15 | 日本化薬株式会社 | ニトログリセリンスプレー剤 |
| DE4018919C2 (de) * | 1990-06-13 | 1994-08-25 | Sanol Arznei Schwarz Gmbh | Nitroglycerin-Spray |
-
1988
- 1988-07-08 HU HU883585A patent/HU199678B/hu unknown
-
1989
- 1989-07-07 GB GB8915632A patent/GB2220949B/en not_active Expired - Lifetime
- 1989-07-07 IT IT8921118A patent/IT1230742B/it active
- 1989-07-07 AT AT0165489A patent/AT401613B/de not_active IP Right Cessation
- 1989-07-07 FR FR8909180A patent/FR2633933B1/fr not_active Expired - Fee Related
- 1989-07-07 JP JP1174325A patent/JPH0651620B2/ja not_active Expired - Lifetime
- 1989-07-07 NL NL8901751A patent/NL8901751A/nl not_active Application Discontinuation
- 1989-07-07 US US07/376,678 patent/US5047230A/en not_active Expired - Lifetime
- 1989-07-07 CH CH2552/89A patent/CH679371A5/de not_active IP Right Cessation
- 1989-07-07 BG BG089108A patent/BG89108A/bg unknown
- 1989-07-07 UA UA4614800A patent/UA11237A/uk unknown
- 1989-07-07 BE BE8900746A patent/BE1003253A3/fr not_active IP Right Cessation
- 1989-07-07 RU SU894614800A patent/RU1837871C/ru active
- 1989-07-10 DE DE3922650A patent/DE3922650A1/de active Granted
-
1994
- 1994-07-15 CY CY176194A patent/CY1761A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104984351A (zh) * | 2015-06-15 | 2015-10-21 | 马应龙药业集团股份有限公司 | 一种硝酸甘油丙二醇溶液的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| BG89108A (bg) | 1993-12-24 |
| DE3922650A1 (de) | 1990-01-11 |
| DE3922650C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-03-04 |
| UA11237A (uk) | 1996-12-25 |
| FR2633933B1 (fr) | 1994-07-22 |
| US5047230A (en) | 1991-09-10 |
| JPH02142726A (ja) | 1990-05-31 |
| FR2633933A1 (fr) | 1990-01-12 |
| GB2220949A (en) | 1990-01-24 |
| IT1230742B (it) | 1991-10-29 |
| AT401613B (de) | 1996-10-25 |
| NL8901751A (nl) | 1990-02-01 |
| ATA165489A (de) | 1996-03-15 |
| GB2220949B (en) | 1992-01-22 |
| BE1003253A3 (fr) | 1992-02-11 |
| CH679371A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-02-14 |
| RU1837871C (ru) | 1993-08-30 |
| JPH0651620B2 (ja) | 1994-07-06 |
| HU199678B (en) | 1990-03-28 |
| IT8921118A0 (it) | 1989-07-07 |
| GB8915632D0 (en) | 1989-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5047230A (en) | Aerosol composition comprising nitroglycerin as active ingredient | |
| JP6295314B2 (ja) | 治療薬を送達するための方法および組成物 | |
| MX2007011112A (es) | Metodo para tratar queratosis actinica. | |
| US20140323472A1 (en) | Methods and compositions for the delivery of a therapeutic agent | |
| JP2000516262A (ja) | エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物 | |
| US20150272909A1 (en) | Pharmaceutical Composition Containing Sympathomimetic Amine Salt and Co-distillable Additive | |
| IE65273B1 (en) | Hydrophilic aqueous pump spray containing nitroglycerin | |
| AU750361B2 (en) | Nasal melatonin composition | |
| GB2162745A (en) | Nasal compositions | |
| IE65420B1 (en) | Nitroglycerin spray | |
| JP2973077B2 (ja) | ビタミンｅ製剤組成物 | |
| KR101625926B1 (ko) | 포스포디에스터라제 타입-5 억제제의 경피 전달을 향상시키는 방법 및 포스포디에스터라제 타입-5 억제제의 경피 전달을 향상시키는 개선된 약학적 조성물 | |
| AP382A (en) | A pharmaceutical composition comprising a benzopyran-3-OL. | |
| HU190513B (en) | Process for producing of new preparates consisting of hydrogenised ergot-alcaloids and hepharine with therapeutical effect | |
| AU2018202245A1 (en) | Methods and compositions for the delivery of a therapeutic agent | |
| AU4591602A (en) | Nasal melatonin composition | |
| HK1011620B (en) | Stabilized medicinal aerosol solution formulations |